Increased risk of lymphoproliferative disorders following the use of OKT3: Association with cumulative dose
Post-transplantation lymphoproliferative disorder (PTLD) is a frequently fatal complication of immunosuppression . The term describes Epstein–Barr virus associated B-lymphoproliferations occurring after organ transplantation. The disease has assumed increasing clinical importance in view of the constantly rising number of organ transplant recipients and the development of highly potent and specific immunosuppressive drugs. Continued, uncontrolled EBV-driven proliferation of B-cells in the absence of adequate T-cell control has been proposed as a mechanism for the development of PTLD by Klein and others [2, 3]. As proliferation continues, clones with a growth advantage emerge, and a monoclonal population eventually predominates. This model is capable of at least partially explaining many of the otherwise puzzling clinical and pathologic features of this disease.
KeywordsLymphoproliferative Disorder Rejection Episode Organ Transplant Recipient Acute Cardiac Allograft Rejection Prophylactic OKT3
Unable to display preview. Download preview PDF.
- 4.Armitage JM, Kormos RL, Stuart RS et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. Journal of Heart & Lung Transplantation 1991; 10: 877–886.Google Scholar
- 12.Renlund DG, O’Connell JB, Gilbert EM et al. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3. Transplantation 1989; 47: 599–605.PubMedCrossRefGoogle Scholar
- National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135.Google Scholar
- 19.Swinnen LJ, Fisher SG, Fisher RI, Koch D, Costanzo MR. Elimination Of OKT3 Induction Therapy: Impact On The Incidence Of Lymphoma Following Cardiac Transplantation. J Heart Lung Transplant 1994; 13 No. 1(2)(abs 148): S68 (abstract).Google Scholar
- 20.Swinnen LJ, Fisher RI. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation. [Review]. Current Opinion in Nephrology & Hypertension 1993; 2: 670–678.Google Scholar
- 23.Alfrey EJ, Friedman AL, Grossman RA et al. A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder Transplantation 1992; 54: 250–253.Google Scholar
- 26.Rosenthal JT, Wilkinson AH, Canfield CW. Fulminant Epstein-Barr Virus-Associated Post-Transplant lymphoproliferative Disorders Following OKT3 Therapy. ASTP Annual Meeting 1991; 74 (abs).Google Scholar